Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) saw an upside of 1.87% to $14.18 after adding $0.26 on Monday. The 5-day average trading volume is 875,255 shares of the company’s common stock. It has gained $14.22 in the past week and touched a new high 3 times within the past 5 days. An average of 1,206,279 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,622,037.
CPRX’s 1-month performance is 15.00% or $1.89 on its low of $12.16 reached on 07/11/23. The company’s shares have touched a 52-week low of $10.50 and high of $22.11, with the stock’s rally to the 52-week high happening on 01/13/23. YTD, CPRX has lost -23.76% or -$4.38 and has reached a new high 6 times. However, the current price is down -35.87% from the 52-week high price.
Insider Transactions
CPRX stock investors last saw insider trading activity on May 15.MCENANY PATRICK J (President and CEO) most recently sold 26,151 shares at $13.23 per share on May 15. This transaction cost the insider $345,978. Director, Tierney David S, sold 30,000 shares at a price of $16.83 on Apr 05. Then, on Mar 29, VP, Treasurer and CFO GRANDE ALICIA sold 50,000 shares at a price of $16.70 per share. This transaction amounted to $835,100.
Valuation Metrics
CPRX stock has a beta of 1.12. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5.73 while the price-to-book (PB) in the most recent quarter is 4.49, with the price to cash flow ratio at 12.30.
Catalyst Pharmaceuticals Inc.’s quick ratio for the period ended March 30 was 3.30, with the current ratio over the same period at 3.50. In terms of profitability, the gross margin trailing 12 months is 85.00%. The trailing 12-month EBITDA margin is 48.24% while for the period ending March 30, Catalyst Pharmaceuticals Inc.’s operating margin was 46.80%. The firm’s gross profit as reported stood at $179.81 million against revenue of $214.2 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 55.22% to $29.57 million, while revenue of $25.47 million was 13.87% off the previous quarter. Analysts expected CPRX to announce $0.32 per share in earnings in its latest quarter, but it posted $0.41, representing a 28.10% surprise. EBITDA for the quarter stood at more than $42.21 million. CPRX stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 73.57 million, with total debt at $3.81 million. Shareholders hold equity totaling $106.08 million.
Let’s look briefly at Catalyst Pharmaceuticals Inc. (CPRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 67.92% to suggest the stock is trending Neutral, with historical volatility in this time period at 31.22%.
The stock’s 5-day moving average is $13.78, reflecting a +2.82% or $0.39 change from its current price. CPRX is currently trading +12.95% above its 20-day SMA, -4.24% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +21.02% and SMA200 by+10.06%.
Stochastic %K and %D was 77.39% and 68.41% and the average true range (ATR) pointed at 0.41. The RSI (14) points at 63.46%, while the 14-day stochastic is at 100.00% with the period’s ATR at 0.43. The stock’s 9-day MACD Oscillator is pointing at 0.19 and 0.24 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX), ROTH Capital downgraded it to a Neutral rating. They previously had a Buy rating on the stock. Analysts offering their rating for CPRX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CPRX as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is CPRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $15.00 and a high of $25.00, with their median price target at $24.00. Looking at these predictions, the average price target given by analysts is for Catalyst Pharmaceuticals Inc. (CPRX) stock is $22.40.
